In April 2018 Vizimpro (dacomitinib) was approved by the European Medicines Agency (EMA) as a first-line treatment of adult patients with metastatic EGFR-positive advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations. It was also approved in U.S. and Japan.
This January, the Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on the use of Vizimpro (dacomitinib). Soon this medicine will be available in the E.U. For further details about Vizimpro (dacomitinib), please click here.